Protalix appoints Gilad Mamlok as SVP & CFO effective Aug 24, 2025, succeeding Eyal Rubin

Protalix BioTherapeutics, Inc.

Gilad Mamlok appointed Senior VP & CFO, effective August 24, 2025.
He succeeds Eyal Rubin, who resigned to pursue other opportunities.
Mamlok brings 30 years experience, previously CFO of TytoCare and Sol-Gel Technologies.
He receives monthly base salary of NIS 81,000 (~$24,066) plus discretionary bonus and options for 597,990 shares at $1.45.
Options vest over 3 years, accelerated upon change of control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.